Qufora lifts long-term goals despite supply challenges

The medtech firm, which provides solutions for people with chronic bowel disorders, had considerable 2021 topline growth, and is now adjusting its goals for the future.
Lena Lachenmeier, CEO of Qufora | Photo: Qufora / PR
Lena Lachenmeier, CEO of Qufora | Photo: Qufora / PR
by christopher due karlsson, translated by daniel pedersen

Qufora, formerly known as MBH-International, has exited 2021 with significant advances on its top line.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading